Spiro had no effect on total urinary cortisol metabolite excretion, 11β-hydroxylase, 11β-HSD type 1 and 2 activity.
Conclusions
Aldo and cortisol are positively associated with BP suggesting that adrenal hyperactivity may in part explain the increased cardiovascular risk in patients with early end-stage CKD. Addition of Spiro had no effect on glucocorticoid metabolism or total 24h corticosteroid production. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In chronic kidney disease (CKD) the renin-angiotensin-aldosterone system (RAAS) becomes progressively activated with decreasing kidney function 1 and angiotensin II (AngII) and aldosterone (Aldo) have emerged as important drivers of both kidney disease progression and increased cardiovascular mortality [2] [3] [4] . Consequently, RAAS inhibition by angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) remains the mainstay of treatment. However, RAAS inhibition by ACEi or ARBs is only partial and a recent study suggests that addition of the mineralocorticoid receptor antagonist (MRA) spironolactone (Spiro) in CKD patients already treated with an ACEi and ARB further reduces markers of renal disease progression 5 . Similarly, the use of MRAs in heart failure patients in addition to established treatment regimens including ACEi and ARBs has been shown to dramatically improve survival 6, 7 .
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One important mode of action of MRAs in CKD patients is by lowering blood pressure through blockade of renal MR in epithelial cells of the distal nephron. The MR has similar affinities for mineralocorticoids and glucocorticoids in vitro 8 and is only protected from glucocorticoid activation by the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) which inactivates cortisol to cortisone. Reduced activity of 11β-HSD2 results in glucocorticoid mediated MR activation and has been described in selected patients with salt sensitive essential hypertension 9, 10 . In CKD patients 11β-HSD2 activity 11, 12 and expression 13 declines with progressively impaired renal function suggesting that in these patients blood pressure and renal damage may be partly driven by glucocorticoid induced MR activation. Therefore this mechanism provides a rationale for the incremental benefit of MRAs on lowering blood pressure in CKD patients.
Besides MR blockade, animal and in vitro studies also suggest that Spiro and its active metabolites can also inhibit steroidogenic enzymes including 11β-hydroxylase and thereby may impact on corticosteroid hormone synthesis 14, 15 . However, so far this has never been investigated in humans. In addition, studies in healthy subjects suggest that hippocampal MR may play a role in the modulation of hypothalamopituitary-adrenal (HPA) drive 16, 17 but so far this has never been demonstrated in patients on long-term low-dose Spiro treatment.
Here we studied corticosteroid hormone secretion and metabolism in CKD patients with mild-moderate renal impairment at baseline and following treatment with low 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   5 dose Spiro. We hypothesised that some of the beneficial effects of Spiro may relate to changes in cortisol secretion and/or metabolism.
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Methods

Study design
The study protocol and subjects have been reported as part of an evaluation of the effect of Spiro on left ventricular mass and aortic stiffness in CKD patients 18 A spironolactone dose of 25mg was chosen in this study as previously low dose spironolactone has been shown to be safe and clinical effective in patients with heart During the open-label run-in phase, 1 patient developed serious hyperkalemia (potassium 6.5 mmol/l) and was withdrawn, 6 (5%) patients had potassium levels between 5.5 and 5.9 mmol/l and were switched to spironolactone on alternate days as per protocol. On blinded treatment, 4 patients had potassium levels between 5.5 and 5.9 mmol/l that required a dose reduction to alternate day treatment. After unblinding, two of these 4 patients were found to have received placebo. After randomization, no patients were withdrawn because of hyperkalemia, and there were no reported side effects, including gynecomastia or menstrual disturbances. The protocol was approved by South Birmingham Local Research Ethics Committee and all patients gave written informed consent.
Blood Pressure
Office brachial blood pressure was recorded with the subject lying supine after 10, 20 and 30 minutes in the non-dominant arm using a validated oscillometric sphygmomanometer (Dinamap® Procare, GE). In addition, all subjects underwent 24 hour ambulatory BP monitoring (Meditech® ABPM-04) at baseline and at week 40.
Biochemical assays
Plasma renin activity (PRA) was measured by an in-house antibody trapping technique in the presence of added excess renin substrate 20 (coefficient of variation:
3.4%
). An in-house radioimmunoassay was used for plasma angiotensin II as previously described 21 . Angiotensin II was pre-extracted from plasma before assay (coefficient of variation: 10%). Plasma aldosterone was measured with a solid-phase (coated tube) radioimmunoassay kit supplied by Diagnostic Products (UK) Ltd (coefficient of variation: <8.3%).
Urinary steroid metabolites
Mineralocorticoids and glucocorticoids are metabolised by various enzymes and are excreted as metabolites in the urine. The main urinary metabolites of mineralo-and glucocorticoids including their precursors were measured by gas chromatography/mass spectrometry (GC/MS) as described previously 22 provides a reflection of cortisol secretion rate. The ratio of tetrahydrometabolites of cortisol (THF + 5α-THF) to those of cortisone (THE) provides a reflection of 11β-HSD1 activity when considered with the ratio of urinary free cortisol (UFF) to cortisone (UFE), which more accurately reflects renal 11β-HSD2 activity 22 . The ratios of cortols to cortolones and of 11β-hydroxy-etiocholanolone and 11β-hydroxy- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 androsterone combined to 11oxo-etiocholanolone also reflect 11β-HSD1 activity 23 .
The activities of 5α-and 5β-reductases can be inferred from measuring the ratio of 5α-THF to THF and androsterone to etiocholanolone. 3α5β-tetrahydro-aldosterone (TH-Aldo) is the main urinary aldosterone metabolite and reflects 24h aldosterone production. The activity of 11β-hydroxylase can be inferred from measuring the ratio of total cortisol metabolites (see above) to tetrahydro-11-desoxycortisol (THS) 24 .
Statistical Analysis
Normally distributed data were expressed as means ± SD (unless stated). Non parametric data were expressed as median (interquartile range) and were log- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Results
All 112 patients enrolled in this study had stage 2 or 3 CKD, were all on either ACEi or ARB treatment for more than 6 months and had normal office blood pressure levels ( Table 1 ). There were no differences in blood pressure or gender distribution between the two groups. However, body weight and BMI was higher in the Spiro compared to the placebo group and in the Spiro group significantly more patients were treated with beta-blockers and statins compared to the placebo group ( Table   1) . As expected, at baseline patients on beta blockers had a significantly lower plasma renin activity (PRA) (median (interquartile range): 23 mU/l (8, 85) vs 82 mU/l (49, 185), p<0.001) and angiotensin II (AngII) levels (4.9 pmol/l (3.1, 8.3) vs 9.9 pmol/l (5.0, 23.1), p<0.05) compared to patients not taking beta-blockers. However by contrast, the plasma aldosterone concentration (PAC) was slightly but significantly higher in patients on beta-blocker treatment (222 pmol/l (152, 300) vs 166 pmol/l (108, 222), p<0.05) suggesting an alternative mechanism of Aldo release in addition to AngII. Analysis of urinary glucocorticoid and mineralocorticoid steroid hormone metabolites between patients on and off beta-blockers did not reveal significant differences suggesting that beta-blockers do not have a major influence on steroid hormone production or metabolism. Comparison of patients on ACEi vs ARB at baseline did not reveal any differences in PRA (64 mU/l (37, 133) Total body weight and BMI were correlated with 24h total glucocorticoid excretion (r=0.407, p<0.001; r=0.296, p=0.003) but not with 5α-reductase activity as assessed by urinary metabolite ratios (Etiocholanolone/Androsterone; 5α-tetrahydro cortisol (5α-THF)/THF). PAC levels were significantly correlated with 24h urinary TH-Aldo excretion (r=-0.214; p=0.036) and furthermore showed a significant negative association with the estimated glomerular filtration rate (eGFR) (r= -0.331, p<0.001).
However, 24h urinary TH-Aldo excretion was not associated with eGFR.
Mean diastolic 24h ambulatory blood pressure (24h ABP) showed a significant correlation with 24h urinary TH-Aldo excretion (Figure 1a) but not with PAC.
Moreover, after adjusting for age, BMI and eGFR, systolic 24h ABP was significantly 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 2) . However, PRA was positively associated with the urinary THF+5αTHF/THE ratio (Figure 2) .
24 patients were on stable glucocorticoid treatment for their underlying kidney disease throughout the study period. However, inclusion or exclusion of glucocorticoid treated patients did not have a significant effect on the analysis of steroid hormone metabolites (total GC excretion, TH-Aldo, enzymatic activities)
between the placebo and Spiro group. Treatment with Spiro compared to placebo significantly reduced both systolic and diastolic 24h ABP despite a significant increase in circulating PRA, AngII and aldosterone levels ( Table 2) . Induction of the renin angiotensin aldosterone system (RAAS) was reflected by a significant increase in 24h urinary TH-Aldo excretion, consistent with an increased aldosterone synthase (AS) activity ( Table 2) . By contrast, Spiro had no effect on global 11β-hydroxylase, 11β-HSD type 1 and 2 activity or total cortisol metabolite excretion as assessed by 24h urinary steroid hormone excretion. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Discussion
In this study we assessed corticosteroid hormone secretion and metabolism in CKD patients on stable treatment with ACEi or ARB before and after addition of Spiro by means of urinary steroid hormone metabolite analysis which allows assessment of cumulative 24h steroid hormone production and, secondly, an estimation of steroid hormone enzyme activities.
As expected, 24h urinary TH-Aldo excretion correlated with PAC although this association was weak. A possible explanation for this weak association could be that the 24h urine collection for TH-Aldo was performed on a different day than blood sampling for circulating aldosterone was done. Additionally, Aldo levels are stimulated by ACTH during stress such as a venous puncture which is likely to vary between individuals. Circulating Aldo concentrations have previously been shown to correlate with blood pressure in black hypertensive 25 and PCOS 26 patients.
However, we did not find a correlation of PAC with systolic or diastolic 24h ABP. In this study lack of association might be explained by the interfering effects of ACEi and ARB on the RAAS and variable stress induced PAC fluctuations during blood sampling. Nevertheless, cumulative 24h urinary TH-Aldo excretion reflecting 24h
Aldo production was indeed positively correlated with 24h blood pressure as well as PAC. It was recently reported that Aldo levels in CKD patients treated with an ACEi are lower compared to ARB treated patients 27 . However, in our study we did not find any significant differences in PAC or urinary TH-Aldo excretion, suggesting that ACEi and ARBs have a similar effect on Aldo secretion.
Total urinary 24h cortisol metabolite excretion is a well established measure to assess daily cortisol production rate and thus reflects activity of the hypothalamopituitary-adrenal (HPA) axis. In agreement with previous studies, we found total glucocorticoid metabolite excretion to be correlated with total body weight and BMI 28 .
Furthermore, 24h glucocorticoid secretion rate was positively correlated with 24h systolic blood pressure after correction of potential confounders such as age, BMI, and eGFR, suggesting that increased total glucocorticoid production as a result of increased HPA activity is implicated in blood pressure regulation in CKD patients.
Although the vast majority of patients with Cushing's syndrome exhibit hypertension 29 , increased 24h cortisol production within the physiologic range has to our knowledge not been associated with blood pressure so far. Increased HPA-drive may therefore be a novel risk factor in CKD patients by driving blood pressure levels.
These findings are in line with a recent report in which high yet within the normal 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w range serum cortisol levels were found to be associated with an adverse outcome in heart failure patients 30 . Further clinical studies are urgently needed to better define and understand the mechanisms of high-normal as opposed to low-normal cortisol levels on blood pressure and ultimately cardiovascular risk in these patients.
Previous studies on glucocorticoid metabolism in CKD patients suggest that 11β-HSD2 activity 11, 12 and expression 13 declines with reduced GFR which in turn may lead to increased MR activation by glucocorticoids leading to increased sodium retention and blood pressure. In our study we did not find a correlation between renal function and the UFF / UFE ratio reflecting renal 11β-HSD2 activity. This is most likely explained by the relatively mild impairment in renal function in our cohort, whereas cohorts in previous studies included patients with more severe renal impairment as well as patients on haemodialysis.
Following Spiro treatment all components of the RAAS were significantly upregulated including PRA, AngII and PAC levels. Consistent with a RAAS activating effect, total 24h urinary TH-Aldo excretion was also significantly increased in the Spiro but not the placebo group. Our findings are in good agreement with a recent report on the neurohormonal effects of Spiro in patients with congestive heart failure and on stable ACEi treatment, which showed increased AngII and Aldo levels following Spiro treatment 31 . These findings suggest that MR blockade by Spiro results in a compensatory stimulation of the RAAS despite tonic inhibition by ACEi and ARBs. However, the degree of compensation inflicted by Spiro is not complete as both diastolic and systolic 24h ABP were reduced compared to baseline.
Previous reports suggested that Spiro and its metabolites exert direct inhibitory effects on steroidogenic enzymes 14, 15 . Here, using urinary steroid hormone metabolites as a surrogate Spiro did not exert an obvious direct inhibitory effect on 11β-hydroxylase. The most likely explanation for this finding may be that the Spiro dose used in this study was too low to exert a measurable effect on 11β-hydroxylase compared to previous studies.
However, by contrast, we found an increased aldosterone synthase (AS) activity following Spiro treatment. AS is the final enzyme involved in Aldo production by converting 11-deoxycorticosterone (DOC) into aldosterone in the zona glomerulosa and is regulated by circulating AngII which was also significantly increased following
Spiro. This finding is consistent with in vitro studies which show increased expression of AS following AngII treatment 32 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 13 Compared to baseline, Spiro treatment did not alter total urinary 24h cortisol metabolite excretion in this study. The main conclusion that can be drawn from this observation is that MR blockade does not seem to interfere with the negative feedback mechanism of cortisol on the HPA axis. Although the hypothalamus mainly expresses the glucocorticoid receptor (GR) but not the mineralocorticoid receptor (MR) 33 , the hippocampus readily expresses both receptors and is implicated in HPA axis modulation 34, 35 . It is therefore conceivable that the negative feedback of cortisol is not solely mediated through the GR, particularly as the MR in vitro shows a 10 fold higher affinity for cortisol than the GR 36 . A number of studies have addressed the role of the MR in mediating negative cortisol feedback. Most studies have shown a short term stimulatory effect on the HPA axis following canrenoate infusion [37] [38] [39] or spironolactone treatment 16, 17 . However, a recent study assessing the effects of the glucocorticoid receptor (GR) antagonist RU28486 and Spiro alone or in combination on the HPA axis 40 showed that RU28486 and Spiro by themselves had no effect but in combination showed a significant compensatory activation of the HPA axis. It is difficult to compare the findings of these studies with our own results for a number of reasons. First of all we assessed HPA axis activity indirectly by means of urinary steroid metabolite excretion. Moreover, treatment duration and doses of MRAs were considerably different. Our study does not support a major effect of low dose Spiro on HPA axis modulation but equally does not rule out more subtle changes.
Indirect analysis of global 11β-HSD type 1 and 2 activity by means of urinary steroid hormone metabolite ratios did not reveal any significant differences following Spiro treatment. It has been suggested that the ratio of urinary free cortisol to free cortisone (UFF/UFE) more precisely reflects renal 11β-HSD2 activity than the tetrahydro-cortisol (THF) + 5α-THF / tetrahydrocortisone (THE) ratio which is a better surrogate marker for global 11β-HSD1 activity 22, 41 . In the kidney the enzyme 11β-HSD2 protects the MR from illicit cortisol binding and thereby ensures Aldo specificity. Loss of function mutations are the underlying cause of severe hypertension and hypokalaemia in AME patients, whereas polymorphisms in HSD11B2 encoding for 11β-HSD2 have been associated with salt-sensitive essential hypertension 29 . Spiro did not result in downregulation of 11β-HSD type 2 activity, which would allow cortisol to activate the MR and thereby lead to sodium and fluid retention, suggesting that only RAAS activation but not modulation of 11β-HSD2 in the kidney is involved in compensating MR antagonism.
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Clinical Endocrinology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Interestingly, global 11β-HSD1 activity was correlated with PRA in this study. We are not aware of a direct interaction of 11β-HSD1 activity and PRA but one could speculate that 11β-HSD1 activity and PRA are regulated by a common factor.
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